医薬品リファレンス
Regorafenib
Regorafenib is a medicine in the class oncology. It is used for colorectal cancer.
- 薬効分類: Oncology
- 効能・効果: colorectal cancer
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01EX05
- 一般的な剤形
- 錠剤
- 一般的な規格
- 40 mg
- 既知の相互作用
- 118 (重大: 41 · 中等度: 60 · 軽度: 17)
- 商品名
- 5
- 国・市場
- 5
何に使われるか
作用のしくみ
Tyrosine kinase inhibitor; shown to inhibit activity of membrane-bound and intracellular kinases involved in normal cellular functions and in pathological processes (eg, oncogenesis, tumor angiogenesis)
成人の通常用量（添付文書の要約）
160 mg (four 40-mg tablets) PO qDay for the first 21 days of each 28-day cycle
妊娠と授乳
- 妊娠
- Unsafe Can cause fetal harm: no human data, but it caused total pregnancy loss and malformations (heart, kidney, skeleton, cleft palate) in rats and rabbits at below human exposure. Avoid; use effective contraception during and for 2 months after treatment (men too).
- 授乳
- Unsafe No human milk data; it passes into rat milk. Over 99% protein bound, but a metabolite with a half-life of up to 70 hours could build up in the infant. Do not breastfeed during treatment and for 2 weeks after the last dose.
報告されている副作用
- Asthenia
- Anemia
- Lymphopenia
- Increased AST
- Proteinuria
- Hypocalcemia
注意が必要な方
- Increased risk of infections reported; most common infections include urinary tract infections, nasopharyngitis, mucocutaneous and systemic fungal infections and pneumoni
- May cause severe drug-induced liver injury with fatal outcome
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (118)
- Apalutamide + Regorafenib Major
- Atazanavir + Regorafenib Major
- Carbamazepine + Regorafenib Major
- Clarithromycin + Regorafenib Major
- Conivaptan + Regorafenib Major
- Dabrafenib + Regorafenib Major
- Darunavir + Regorafenib Major
- Duvelisib + Regorafenib Major
- Efavirenz + Regorafenib Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Regorafenib Major
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Regorafenibの完全なモノグラフ（用量、妊娠・授乳、副作用、警告、すべての相互作用）を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Paediatric dosing
- Patient counselling points
- Food interactions
WebでPro+を7日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
関連するクイックリード
よくある質問
What is Regorafenib used for?
Regorafenib is a medicine in the class oncology. It is used for Colorectal cancer, Gastrointestinal tumors, Hepatocellular carcinoma.
What side effects have been reported with Regorafenib?
Asthenia, Anemia, Lymphopenia, Increased AST, Proteinuria, Hypocalcemia.
Can Regorafenib be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. Can cause fetal harm: no human data, but it caused total pregnancy loss and malformations (heart, kidney, skeleton, cleft palate) in rats and rabbits at below human exposure. Avoid; use effective contraception during and for 2 months after treatment (men too). Breastfeeding: Unsafe. No human milk data; it passes into rat milk. Over 99% protein bound, but a metabolite with a half-life of up to 70 hours could build up in the infant. Do not breastfeed during treatment and for 2 weeks after the last dose.
What does Regorafenib interact with?
MediHelp lists 118 known interactions for Regorafenib. Major: 41 · Moderate: 60 · Minor: 17. The most serious include Apalutamide, Atazanavir, Carbamazepine.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
